COVID-19 & Respiratory Infections Questions

COVID overlaps heavily with flu and colds — fever, cough, tiredness, body aches, sore throat. Loss of taste or smell is more distinctive to COVID. Only a test can confirm which virus is causing symptoms. The main practical difference: COVID has caused more severe illness in older adults and people with chronic conditions, and can lead to longer-lasting fatigue (long COVID) even after mild infection.

Yes, especially if you'll be around older adults, pregnant women, or people with weak immunity — knowing lets you avoid spreading. Testing also matters if symptoms are severe enough that antiviral treatment might help (which needs to start early). Home rapid tests are widely available; PCR tests are more accurate. If you test positive, isolate as advised and monitor for worsening symptoms.

Long COVID is symptoms lasting more than 12 weeks after infection — commonly fatigue, brain fog, breathlessness, palpitations, and sleep problems. It can happen after even mild initial illness. Treatment is symptomatic and often multi-disciplinary (physiotherapy, pacing, mental health support, sometimes specific medications for individual symptoms). Long COVID clinics exist in major cities. Most people gradually improve over months but a subset have prolonged symptoms.

Keep their vaccinations current (annual flu, COVID boosters, pneumococcal). Wash hands before visiting, especially with a cough or cold. Skip in-person visits when you or family members are actively ill. Improve ventilation at home. Get help with chronic conditions well-controlled — diabetes and heart disease worsen respiratory infection outcomes. Have a plan for who takes them to hospital if needed.

Difficulty breathing at rest, chest pain, confusion, blue lips or fingertips, inability to keep fluids down, oxygen saturation below 94% on a home pulse oximeter, or fever that's very high or lasting more than a few days. In children, look for fast breathing, chest indrawing, or refusal to feed. Don't wait — respiratory illness can worsen fast, especially in older adults.

Latent TB means the M. tuberculosis bacteria are in your body but contained by your immune system inside granulomas, you have no symptoms, are not infectious, and cannot spread the disease. Chest X-ray is usually normal; TB is detected only through Mantoux test or IGRA blood test. Active TB means the bacteria have broken out of containment and are multiplying, causing symptoms (persistent cough, weight loss, night sweats, low-grade fever) and making you infectious to others. Roughly 5-10% of people with latent TB will develop active TB at some point in their lifetime, with the risk highest in the first 2 years after exposure and in anyone whose immune system weakens (HIV, diabetes, steroids, TNF inhibitors, aging). Whether latent TB needs treatment depends on individual risk. WHO recommends preventive treatment for household contacts of active TB cases, HIV-positive people, people starting immunosuppressive drugs, and healthcare workers with recent conversion. India's NTEP is expanding preventive TB treatment access, particularly for household contacts.

A positive RDT confirms malaria and shifts focus immediately to two things: (a) determining severity, a doctor evaluates whether it is uncomplicated malaria (treatable at home with oral antimalarials) or severe malaria (needs hospitalisation and IV artesunate). Severe malaria indicators include altered consciousness, seizures, jaundice, dark urine, breathing difficulty, or extreme weakness. (b) identifying species, this determines the drug regimen. For P. falciparum in India, artemisinin combination therapy (ACT) is first-line; for P. vivax, chloroquine plus primaquine (primaquine treats the dormant liver stage to prevent relapse). The doctor will also order a follow-up blood smear to quantify parasite load and check response to treatment at day 3. Do not self-treat with over-the-counter antimalarials on a positive RDT, the wrong drug or dose can drive resistance and worsen outcomes.

RDTs use protein-based antibodies that degrade at high temperatures, accuracy drops meaningfully when kits are stored above 30°C for extended periods, which is a real issue in Indian summers and in rural clinics without air conditioning. Storage above 40°C can produce false negatives even for kits well within their expiry date. Practical implications: kits held in unrefrigerated pharmacy shelves during peak summer months (April-June) may perform worse than the manufacturer's stated sensitivity; kits transported without cold-chain protection in field settings often lose reliability. This is why WHO recommends RDT lot testing before deployment in endemic areas. For patients: if an RDT result seems inconsistent with your clinical picture, ask for a blood smear rather than trusting the RDT alone, the smear does not have storage-related accuracy issues.

Malaria RDT kits are available in India but not typically sold for home use, they are meant for clinical or field-worker settings and are usually sold to hospitals, primary health centres, NGOs, and pharmacies for point-of-care testing rather than direct-to-consumer. Even where available at retail pharmacies, home use is not recommended because: interpreting a faint test line correctly needs practice, a negative result does not rule out early-stage malaria and needs follow-up, and any positive result immediately needs a doctor visit for treatment (antimalarials are prescription-only). Practical alternative: same-day RDT plus blood smear at a diagnostic lab or general practitioner clinic is inexpensive and available in most Indian cities. Do not delay treatment while trying to diagnose at home if you have symptoms consistent with malaria after mosquito exposure.

Getting infected and getting sick are two different things. Roughly one-third of the global population carries M. tuberculosis in latent form after some exposure, but only 5-10% ever develop active disease. Whether you progress from infection to active disease depends on multiple factors: immune status (HIV infection multiplies risk 20-30 times, diabetes doubles risk, aging weakens immunity), nutritional status (malnutrition dramatically increases risk), co-existing lung damage (smoking, silicosis, previous TB), genetic factors (specific HLA variants affect susceptibility), medications suppressing immunity (steroids, chemotherapy, TNF inhibitors), and the initial infecting dose. In India, the confluence of high HIV in some regions, high diabetes prevalence (over 100 million adults), household crowding, and undernutrition explains why India carries such a disproportionate share of the global TB burden despite decades of control efforts.

BCG (Bacillus Calmette-Guérin) vaccine has real but limited effectiveness. It reliably prevents severe childhood forms of TB. TB meningitis and disseminated (miliary) TB, with efficacy of 60-80%. It is far less effective at preventing adult pulmonary TB, with published efficacy ranging from 0% to 80% depending on the population studied, the variability itself is a major research puzzle, possibly related to prior exposure to environmental mycobacteria in different geographies. Despite this variability, India continues universal BCG vaccination at birth because the severe childhood TB prevention justifies it in a high-burden country; deaths from meningitis or miliary TB in unvaccinated Indian infants would be substantial. Improved TB vaccines are in active development globally (M72/AS01E is in phase 3 trials), but until one is approved, BCG remains standard for Indian newborns and provides genuine protection for the childhood forms that matter most in the neonatal period.

MDR-TB is TB resistant to at least isoniazid and rifampicin, the two most powerful first-line drugs. This resistance usually develops when patients receive inadequate treatment (wrong drugs, wrong doses, insufficient duration, or interruption), surviving bacteria multiply and become resistant. XDR-TB (extensively drug-resistant TB) is even more resistant, adding resistance to fluoroquinolones and injectable second-line drugs. India has among the largest number of MDR-TB cases globally. Treatment takes 9-24 months (vs 6 months for drug-sensitive TB), involves 4-7 medications simultaneously, causes more side effects, costs significantly more, and has lower cure rates (roughly 60-75% vs 85-95% for drug-sensitive TB). India's NTEP provides free MDR-TB diagnosis (GeneXpert MTB/RIF plus line probe assays) and treatment through dedicated DR-TB centres. Key patient rule: never stop TB treatment early even when feeling better, never skip doses, never take TB medications from unknown sources, creating MDR-TB harms both the patient and the community for decades.

Modern malaria RDTs have sensitivity of roughly 90-95% for detecting Plasmodium falciparum at typical fever-onset parasite levels, meaning they catch most cases but can miss around 5-10%. Sensitivity for P. vivax is lower, around 80-90%, because the antigens vary more across strains. Sensitivity drops significantly when parasite counts are very low (early in the illness or in asymptomatic carriers). Blood smear microscopy remains the gold standard, with sensitivity approaching 95% in expert hands and the ability to identify species and quantify parasite load. In practice, RDT is the fast first test almost anywhere in India; blood smear confirms the diagnosis and guides treatment intensity. A negative RDT with persistent malaria-suggestive symptoms should always trigger a follow-up smear rather than being taken as definitive.

Very urgent, especially if you have travelled to sub-Saharan Africa, the Indian North-East, Odisha, Chhattisgarh, or parts of South-East Asia where P. falciparum is common. Get tested the same day. P. falciparum malaria can progress to severe disease within 24-72 hours of first symptoms, cerebral malaria, kidney failure, severe anaemia, ARDS. Tell the doctor exactly where you travelled, when, and whether you took prophylaxis. If travel was to a P. vivax or P. ovale region, symptoms can appear weeks to months after return because these species can lie dormant in the liver, any unexplained fever within a year of travel to an endemic zone warrants a malaria test, not just antibiotics for a presumed viral illness.

A negative RDT does not rule out malaria, especially in the first 24-48 hours of illness or in P. vivax infection where parasite levels can be low. Next steps: (a) request a thick and thin blood smear read by an experienced microscopist, this is more sensitive than an RDT and identifies the species; (b) if smear is also negative but fever continues past 48 hours, repeat the smear, parasitemia rises with each fever cycle and can become detectable; (c) discuss PCR testing at a tertiary centre if smears remain negative but symptoms are strongly suggestive; (d) in parallel, work up other causes of fever in India, dengue, typhoid, chikungunya, leptospirosis, urinary infection, since these can co-exist or mimic malaria.

In government hospitals, both RDT and blood smear are typically free or nominal. In private labs, RDT and blood smear together are usually affordable and results come back the same day. RDT within 20-30 minutes, smear within 2-4 hours if the lab has a technician on shift. PCR is only available at larger hospitals and reference laboratories; it is significantly more expensive and takes 24-72 hours depending on the batch schedule. For anyone with fever in an endemic area, testing should not be delayed by cost, a delayed diagnosis in P. falciparum malaria can escalate to cerebral malaria within days.

The NS1 antigen appears in blood as early as day 1 of fever and stays detectable through roughly day 5-7. That is the window where NS1 is most sensitive. If you have fever with any classic dengue features, sudden high fever, severe body aches (especially behind the eyes), headache, nausea, or a rash, and you are anywhere in India during monsoon or early post-monsoon (June-November), ask your doctor about NS1 on the same day fever starts. Waiting past day 5 makes NS1 progressively less sensitive; after day 7, IgM antibody test becomes more useful. Testing on day 0-1 of fever occasionally gives false negatives because viral load has not yet peaked, a repeat test 24-48 hours later resolves this.

Three different things at three different time points. NS1 detects a viral protein made by the dengue virus itself, positive from day 1-7, catches active infection early. IgM antibody appears from day 5-7 onwards and stays positive for 2-3 months, catches recent infection, useful when NS1 window has passed. IgG antibody appears from day 7-14 and stays positive for years, indicates past infection or immunity, not useful for diagnosing current fever alone. In practice, doctors often order NS1 + IgM together in the first week of fever, since together they cover the whole infection window. IgG is only useful in specific situations like distinguishing primary vs secondary dengue (secondary infection has higher risk of severe dengue).

A positive NS1 confirms dengue and shifts the focus to monitoring for complications, since there is no antiviral treatment. Immediate steps your doctor will typically arrange: (a) baseline CBC to check platelet count and hematocrit; (b) monitoring platelet count daily during the critical phase (day 3-7 of fever), platelets can drop rapidly; (c) hydration guidance, oral or IV fluids as needed, particularly during the fever-defervescence phase which is when severe dengue often develops; (d) avoiding aspirin, ibuprofen, and other NSAIDs because they raise bleeding risk in dengue, paracetamol (acetaminophen) is the only safe antipyretic; (e) hospitalisation if warning signs appear (severe abdominal pain, persistent vomiting, bleeding from gums or nose, lethargy, cold extremities). The critical period is when fever breaks around day 4-6, that is the window to watch most carefully, not the fever itself.

A negative NS1 does not rule out dengue, especially in the first 24-48 hours of fever (viral load may not yet be at detectable levels) or after day 5-7 (NS1 window has closed). Practical next steps: (a) if you tested on day 1-2 of fever, repeat NS1 after 24-48 hours, sensitivity improves as viral load rises; (b) if fever has been going 5+ days, ask for IgM antibody test which becomes positive around day 5-7; (c) simultaneously rule out other Indian monsoon fevers with overlapping symptoms, malaria (blood smear + RDT), typhoid (Widal or blood culture), leptospirosis, chikungunya, and viral hepatitis all present similarly. Do not assume 'just viral fever' if fever continues past 48-72 hours without a diagnosis, return to your doctor for expanded workup rather than waiting it out at home.

NS1 (nonstructural protein 1) is a glycoprotein made by the dengue virus during its replication inside human cells. It is secreted into the bloodstream in large quantities from day 1 of infection, reaching detectable levels typically within 24 hours of fever onset and remaining detectable through roughly day 5-7. This early appearance makes NS1 uniquely useful because it fills the diagnostic gap before your body has produced detectable antibodies (IgM appears around day 5-7, IgG around day 7-14). NS1 is highly specific to flaviviruses (dengue, Zika, yellow fever), so a positive result in an Indian patient with fever during dengue season is almost certainly dengue, since Zika and yellow fever are rare here. Testing methods: ELISA is the lab standard (highest sensitivity); rapid diagnostic test (RDT) kits give point-of-care results in 15-30 minutes with slightly lower sensitivity.

Both detect the same NS1 antigen but differ in sensitivity, turnaround, and cost. NS1 ELISA (enzyme-linked immunosorbent assay): performed in a diagnostic laboratory, sensitivity typically 85-95%, results in 4-24 hours depending on lab batching, moderate cost. This is the standard reference test. NS1 rapid diagnostic test (RDT) kits: performed at point-of-care (clinic, small lab, some pharmacies), sensitivity typically 70-85%, results in 15-30 minutes, lower cost. RDTs are useful when time matters and lab access is limited, a positive RDT is highly reliable, but a negative RDT should ideally be confirmed with ELISA if clinical suspicion remains high. In India during dengue outbreaks, RDT-first-then-ELISA-if-negative is a common approach, particularly outside tier-1 cities where lab turnaround can slow the diagnosis.

In principle yes. NS1 tests can show cross-reactivity with other flaviviruses because these viruses share protein structures. In practice for Indian patients this is rarely a clinical issue: Zika virus is uncommon in India (small outbreaks reported), yellow fever is not endemic in India (a few imported cases), and Japanese encephalitis (JE) does exist but the clinical presentation differs enough that dengue vs JE is usually distinguishable clinically. For most Indian patients with fever and a positive NS1 test during dengue season, the result reliably indicates dengue. Where confusion can arise: recent yellow fever vaccination (given for international travel) or recent JE vaccination can occasionally cause transient antibody cross-reactivity, though this affects IgM tests more than NS1 antigen tests. If cross-reactivity is a genuine concern (post-travel, unusual clinical picture), confirmatory testing with dengue-specific PCR resolves it.

A negative NS1 test does not rule out dengue, it needs interpretation in context of when in the illness you tested. Common reasons for a false-negative NS1: (a) tested too early (first 24 hours of fever, viral load still rising below detection threshold); (b) tested too late (after day 5-7, NS1 has cleared from blood but antibodies are now present); (c) secondary dengue infection in someone previously infected with a different serotype, pre-existing IgG antibodies bind NS1 and reduce its detectability; (d) infection with certain P. vivax-like less common serotypes with lower NS1 production. Next steps for a symptomatic patient with negative NS1: repeat NS1 in 24-48 hours if still within day 1-5 window, or add IgM antibody test if past day 5, or PCR testing at a tertiary centre for definitive diagnosis. Do not accept 'ruled out dengue' from a single NS1 without considering timing, one test does not close the case if symptoms strongly suggest dengue.

The three anchor diagnoses in most cases: Hyperthermia related to underlying infection or inflammatory process (as evidenced by elevated body temperature above 38°C, warm skin, tachycardia); Deficient Fluid Volume or Risk for Deficient Fluid Volume related to excessive fluid loss from vomiting and insensible loss from fever (evidenced by decreased urine output, dry mucous membranes, tachycardia, hypotension); and Nausea related to gastrointestinal irritation, drug side effects, or central causes (evidenced by patient report and observed retching). Secondary diagnoses to consider based on presentation: Risk for Electrolyte Imbalance, Acute Pain (headache or abdominal), Imbalanced Nutrition Less than Body Requirements if vomiting is protracted, and Risk for Infection Transmission when the underlying cause is a communicable pathogen. Priority ordering follows Maslow, fluid balance first, then temperature, then comfort.

At minimum every 4-6 hours during the acute phase: temperature (route consistent, oral, axillary, or tympanic; note the route), heart rate, blood pressure (including orthostatic if the patient is ambulant), respiratory rate, oxygen saturation, level of consciousness, and pain score. Fluid balance: strict intake and output charting, urine specific gravity or colour observation, weight if possible daily at the same time. Vomiting characterisation: frequency, volume, colour and content (bilious, coffee-ground, undigested food, blood), and relation to food or medication. Assess mucous membranes, skin turgor, and capillary refill each shift for hydration status. In endemic Indian settings, note any petechiae, rash, or bleeding, early signs of severe dengue that shift the care plan significantly.

Establish IV access early, deteriorating patients can lose the option to hydrate orally quickly. Initiate rehydration per protocol (oral rehydration solution if tolerated; IV normal saline or Ringer's lactate if vomiting persists or dehydration is significant), correcting electrolyte deficits based on baseline labs. Administer prescribed antipyretic (paracetamol is first-line; avoid NSAIDs if dengue is on the differential due to bleeding risk) and prescribed antiemetic (ondansetron is common first-line for adults; metoclopramide alternatives). Cooling measures: tepid sponging if temperature is over 39°C, adequate exposure, ambient temperature control. Send off diagnostic samples early. CBC, electrolytes, urea/creatinine, urine routine, and pathogen-specific tests based on epidemiology (dengue NS1, malaria smear, typhoid Widal or blood culture, stool if diarrhoea present). Document baseline for evaluation.

Objective indicators of successful intervention within 24-48 hours: temperature trending down toward 37.5°C or lower without persistent antipyretic dependence; vomiting frequency reduced by at least 50%, patient tolerating small oral fluid volumes; urine output restored to at least 0.5 mL/kg/hour with clearing urine colour; heart rate and blood pressure normalising toward baseline; improving level of consciousness and patient-reported comfort. Red flags requiring escalation to the treating physician: persistent fever above 39°C beyond 48 hours of appropriate antipyretic use, worsening tachycardia despite fluid replacement, oliguria, altered mental status, new bleeding manifestations (particularly relevant in the Indian dengue season), rising creatinine, or persistent inability to tolerate oral intake. The care plan is not a static document, nursing diagnoses should be re-prioritised as the aetiology clarifies from diagnostic workup.

Neither. Malaria is caused by a single-celled parasite called Plasmodium, technically a protozoan, one of the oldest kinds of life on earth. Five species infect humans: P. falciparum (the most dangerous, common in Africa and parts of India's North-East and eastern states), P. vivax (the most widespread in India, causes relapsing infections), P. ovale, P. malariae, and P. knowlesi (rare, mainly South-East Asian forest exposure). Because it is a parasite and not a bacterium or virus, malaria does not respond to antibiotics or antiviral medicines. It needs specific antimalarial drugs, chloroquine, artemisinin-based combinations, or primaquine, depending on the species and drug-resistance pattern in the region.

The bite injects fewer than a hundred parasite sporozoites into your bloodstream, a tiny number, but they head straight for the liver within an hour. Inside a liver cell, each sporozoite multiplies silently over 7-30 days into tens of thousands of new parasites (merozoites). When the liver cell bursts, those merozoites flood into your bloodstream and start invading red blood cells. Each infected red cell then bursts every 48-72 hours, releasing more parasites, and this is when you first feel sick. So the mosquito bite is small, but the liver stage is a hidden multiplier that turns a handful of parasites into millions before symptoms even begin.

Because the parasite's blood-stage cycle is synchronised. All the infected red blood cells burst at roughly the same time, every 48 hours for P. vivax and P. ovale (tertian fever), 48 hours for P. falciparum (though often less regular), and 72 hours for P. malariae (quartan fever). Each mass rupture releases parasites plus toxic parasite waste products into the bloodstream, which triggers the immune system to spike fever, chills, and shivering, the classic malaria paroxysm. Between paroxysms, the parasite is quietly invading fresh red blood cells and you feel relatively normal. This cyclical pattern is so distinctive that a fever every other day in someone who has been in an endemic area should trigger a malaria test even before other symptoms develop.

Both P. falciparum and P. vivax are prevalent in India but they behave differently. P. falciparum is more common in Odisha, Chhattisgarh, Jharkhand, and the North-East and causes almost all severe and fatal malaria, cerebral malaria, kidney failure, ARDS, severe anaemia. It progresses fast and can kill within days if untreated. P. vivax is more widespread across the country and causes fewer deaths but has two features that matter: relapses can occur months to years after the original infection because dormant liver-stage parasites (hypnozoites) can reactivate, and chronic P. vivax weakens people over time. Any fever after being in a mosquito-endemic area should be tested regardless of which species is more common there, waiting to see if it is just viral fever can be dangerous with P. falciparum.

Ask for a peripheral blood smear as your primary test, thick smear for detection, thin smear for species identification. A rapid diagnostic test (RDT) is a reasonable add-on, especially if you are in a smaller clinic or evening hours when a microscopist may not be available; RDT gives a result in 15-20 minutes. If both are negative but fever and symptoms persist for another 24-48 hours, a repeat smear at a good centre or a PCR test at a tertiary hospital is the next step. Do not rely on RDT alone if your clinical picture is convincing, low-parasitemia infections and non-falciparum species (P. vivax, P. ovale) can be missed by rapid tests.

A negative test can be a real false-negative — the disease is there but the test missed it. The commonest reasons: parasite load is too low to detect (early infection, or partial treatment already given at home), the sample was taken between fever peaks when parasites are hiding inside cells, the RDT antigen has degraded due to bad storage, or the falciparum strain doesn't make HRP2 (a real problem in some African countries and now surfacing globally). Skill matters too — reading a blood smear well takes training. If clinical suspicion is high — persistent fever, recent travel to an endemic area, chills, jaundice — the doctor will repeat the smear every 12–24 hours for up to three days before ruling out malaria, or move to PCR. A single negative test is not enough to close the case.

Confusion, seizures, extreme weakness, breathlessness and dark or reduced urine mean the malaria has turned severe. Cerebral malaria (mostly from P. falciparum) causes altered consciousness, seizures and coma. Other severe features include very low haemoglobin, respiratory distress, kidney failure (sometimes called blackwater fever from dark urine), dangerously low blood sugar and metabolic acidosis. Children under five, pregnant women, elderly people and anyone with a weakened immune system are at highest risk. Any fever plus one of these signs after a mosquito bite or travel to a malaria area needs emergency hospital care — severe malaria can kill within 24 hours if untreated.

A blood test confirms malaria within minutes, and treatment usually cures it in 3–7 days if started early. Doctors diagnose malaria by looking at a stained blood smear under the microscope — this identifies the species and how many parasites are present. Rapid diagnostic tests (RDTs) give a result in 15–20 minutes from a finger-prick sample and are widely used in clinics and endemic areas. PCR is used in complex or research cases. Treatment depends on the species and severity: uncomplicated cases usually get artemisinin-based combination therapy (ACT) for three days; severe malaria needs intravenous artesunate in hospital plus supportive care. P. vivax and P. ovale also need a drug like primaquine to clear liver-stage parasites and prevent relapse.

You cannot confirm it at home — but the pattern of fever and the type of pain give strong clues before a blood test. Malaria fever usually comes in cycles every 48 or 72 hours with shaking chills followed by sweats, and often causes pallor, jaundice or dark urine because red blood cells are being destroyed. Dengue fever is typically sudden, very high (up to 40°C) and continuous rather than cyclic, with severe pain behind the eyes, intense muscle and joint pain ("breakbone fever"), skin rash and sometimes bleeding from the nose or gums. Both start after a mosquito bite. Any high fever lasting more than two days — especially with these clues — needs a same-day blood test to confirm the diagnosis.

Malaria comes from the Anopheles mosquito, which bites mostly at night; dengue comes from Aedes, which bites during the day. The Anopheles mosquito carries Plasmodium parasites and prefers dusk-to-dawn feeding, so bed nets and evening protection matter most for malaria. The Aedes aegypti mosquito carries dengue virus and bites mainly in the early morning and late afternoon, breeding in clean stagnant water inside homes — coolers, flower pots, discarded tyres, plastic containers. That is why dengue control focuses on removing indoor water sources while malaria control leans more on outdoor spraying and bed nets. During monsoon both mosquito populations rise together, which is why dengue and malaria outbreaks often overlap in the same weeks.

Bleeding, confusion, severe abdominal pain, breathing trouble or reduced urine mean the illness has turned severe and needs emergency care. For dengue, warning signs typically appear as the fever drops on day 3–5: severe abdominal pain, persistent vomiting, bleeding from gums or nose, blood in vomit or stool, rapid breathing, cold clammy skin and drop in platelet count. This phase can progress to dengue shock syndrome within hours. For malaria, danger signs include confusion, seizures, extreme weakness, jaundice, dark urine and breathing difficulty — usually pointing to cerebral malaria or severe organ involvement. Any of these signs, in either infection, means hospital admission, not home care.

Malaria has specific drugs that kill the parasite; dengue has no antiviral drug, so treatment is supportive. For malaria, once the species is identified, doctors use artemisinin-based combination therapy (ACT) for three days in uncomplicated cases; severe malaria needs intravenous artesunate. P. vivax also needs primaquine to prevent relapse from liver-stage parasites. For dengue, there is no specific antiviral — treatment focuses on fluids (oral or IV depending on severity), paracetamol for fever, monitoring of platelet count and haematocrit, and hospital care if warning signs appear. Aspirin and ibuprofen are avoided in suspected dengue because they raise the risk of bleeding. Never self-treat suspected malaria or dengue — both need blood-test confirmation and doctor supervision.

Yes — TB can leave the lungs and settle in bones and joints, and the spine is the single most common site. This form is called skeletal or bone TB, and spinal TB specifically is known as Pott's disease. The infection reaches the bone through the bloodstream, usually from a lung or lymph-node source that may itself be silent by the time the bone disease shows up. Around 1–3% of all TB cases involve bone, with the spine accounting for roughly half of these; the hip and knee are the next most common. Because it develops slowly over months, bone TB is often mistaken for ordinary back pain, arthritis or a sports injury, and diagnosis is frequently delayed.

Persistent, deep bone pain that gets worse at night, along with low-grade evening fever, unexplained weight loss and night sweats, are the classic warning signs. In spinal TB the pain is usually in the mid or lower back and doesn't improve with rest or painkillers. Local swelling, restricted movement of the affected joint and eventually a visible bump on the back (kyphosis, or hunchback) can develop as vertebrae collapse. A cold abscess — a soft, painless swelling without redness or warmth — sometimes appears near the spine, groin or thigh. Neurological symptoms like leg weakness, numbness or difficulty passing urine are red flags for spinal cord compression and need urgent evaluation.

MRI is the most sensitive test for bone and spinal TB — it shows early bone marrow oedema, disc destruction, cold abscesses and any pressure on the spinal cord well before X-rays do. X-rays and CT scans help see bone destruction and deformity. To confirm the diagnosis, doctors take a biopsy of the affected bone or the pus from a cold abscess and send it for microscopy, TB culture and molecular tests like GeneXpert MTB/RIF, which also flags rifampicin resistance within hours. Blood tests (ESR, CRP) support the diagnosis but cannot confirm it. Chest X-ray is done to check whether the lungs are also involved, since around half of bone TB cases have a hidden pulmonary focus.

Bone TB is treated with the same four anti-TB drugs used for lung TB — isoniazid, rifampicin, ethambutol and pyrazinamide — but for longer, usually 9 to 12 months in total. The first two months use all four drugs; the remaining months use isoniazid and rifampicin. Bed rest, a brace to support the spine and gradual physiotherapy help protect the bone while it heals. Surgery is reserved for specific situations: severe spinal deformity, spinal cord compression not responding to medicines, large abscesses that need drainage or an unstable spine that needs fusion. Most people recover fully if treatment is started before major bone destruction, so early diagnosis really is the difference between full recovery and permanent disability.

The three highest-priority NANDA-I diagnoses for pulmonary TB are Ineffective Airway Clearance, Risk for Infection Transmission, and Imbalanced Nutrition: Less Than Body Requirements. Ineffective Airway Clearance — related to thick, tenacious sputum and bronchospasm secondary to Mycobacterium tuberculosis infection, as evidenced by productive cough, abnormal breath sounds, and dyspnea — is first priority because impaired airway clearance directly threatens oxygenation and increases the risk of respiratory failure in severe cases. Risk for Infection Transmission is equally critical from a public health standpoint: TB is airborne, and a smear-positive patient can infect 10–15 people per year without proper isolation precautions. Imbalanced Nutrition is third priority because TB is a wasting disease — the infection drives a hypermetabolic state, while anorexia, nausea from antitubercular drugs, and fatigue all reduce oral intake. Additional diagnoses to include: Activity Intolerance (related to weakness, fever and dyspnea), Ineffective Health Maintenance (related to complex 6-month DOTS regimen), and Anxiety (related to stigma and prolonged treatment). In TB-specific NCP examinations, students are expected to identify infection transmission risk as a separate nursing responsibility alongside the patient's own clinical problems.

Infection control is a shared nursing and public health responsibility in TB care. The primary intervention is airborne precaution isolation: the patient should be placed in a negative-pressure single room (or in a well-ventilated room with windows open if a formal isolation room is not available). The nurse must wear an N95 respirator — not a surgical mask — when entering the room; surgical masks protect the patient, not the nurse, from airborne droplet nuclei. Teach the patient to cover the mouth and nose with a triple-layered surgical mask or a tissue when coughing or sneezing (respiratory hygiene/cough etiquette), and to dispose of sputum-soaked tissues in a sealed bag. Handle sputum specimens as biohazard material. Ensure DOTS (Directly Observed Treatment, Short-course) compliance: the nurse or a trained health worker directly watches the patient swallow each dose of antitubercular drugs (Isoniazid, Rifampicin, Pyrazinamide, Ethambutol in the intensive phase). Non-adherence is the leading cause of drug resistance and prolonged infectiousness. Facilitate contact tracing — identify close contacts (household members, co-workers) and refer them for tuberculin skin test or IGRA testing. Document isolation precautions, sputum smear status, and every DOTS administration in the nursing record. Isolation can generally be discontinued once the patient has three consecutive negative sputum smears on separate days and has been on effective therapy for at least two weeks.

Nutritional rehabilitation is essential to TB recovery because undernutrition impairs cell-mediated immunity, which is the primary defence against Mycobacterium tuberculosis. The nurse's role is to assess nutritional status at admission (BMI, mid-upper arm circumference, serum albumin if available) and monitor weekly weight. Set a nutritional goal: TB patients should consume at least 35–40 kcal/kg/day and 1.2–1.5 g protein/kg/day to rebuild lean mass and support immune function. Advise a high-calorie, high-protein diet: pulses, legumes, eggs, fish, chicken, low-fat dairy (paneer, curd), whole grains, and fresh fruits and vegetables rich in vitamins A, C, and E. Isoniazid depletes vitamin B6 (pyridoxine), so ensure the patient is prescribed pyridoxine 25–50 mg daily alongside antitubercular therapy to prevent peripheral neuropathy. Manage common nutritional barriers: nausea and loss of appetite from Rifampicin and Pyrazinamide are worst in the first 2–4 weeks — advise taking drugs with a light snack (not a heavy meal) if nausea is severe; offer small, frequent meals every 2–3 hours rather than three large meals. Refer to a dietitian if BMI is below 17 or if the patient has comorbid diabetes (insulin requirements change as TB treatment progresses and nutrition improves). Document dietary intake and weight weekly; a patient gaining weight steadily is responding to treatment.

Discharge education is critical because TB treatment continues for 6 months (standard regimen) or longer (MDR-TB), entirely at home after the intensive phase. Cover these six areas: (1) Drug adherence — explain that stopping drugs early is the single biggest cause of MDR-TB; link the patient into the local DOTS centre or PHC for continued supervised therapy; give the DOTS worker's contact number. (2) How TB spreads and how to protect the family — open windows for ventilation, sleep in a separate room if possible, wear a mask during the infectious period (first two weeks of treatment), and avoid crowded enclosed spaces. (3) Recognition of drug side effects — yellow eyes or urine (rifampicin colours urine orange-red, which is normal, but yellow sclera means hepatotoxicity; stop drugs and report immediately), tingling hands or feet (pyridoxine deficiency from isoniazid — take B6 supplement), visual disturbance (ethambutol-related optic neuritis — report immediately). (4) Diet — high-protein, high-calorie meals; no alcohol (increases hepatotoxicity risk). (5) Follow-up schedule — sputum smear at 2 months, 5 months and 6 months; chest X-ray at 2 and 6 months; liver function test monthly in the first 2 months. (6) TB notification — inform the patient that TB is a notifiable disease; the treating facility reports to the district TB officer, which triggers contact tracing for household members.

Yes, most adults benefit from at least the hepatitis B vaccine, and many should also get hepatitis A depending on their risk. Hepatitis B is a major cause of chronic liver disease, cirrhosis and liver cancer, and it spreads through blood, sexual contact, and shared needles — the WHO recommends universal vaccination for all adults who were not vaccinated in childhood. Hepatitis A spreads through contaminated food and water, so people travelling to areas with poor sanitation, those with chronic liver disease, healthcare workers, food handlers, and men who have sex with men are strongly advised to get it. Vaccination is safe, inexpensive, and gives long-lasting protection — usually decades — from two life-changing infections.

Hepatitis A needs 2 doses six months apart; hepatitis B needs 3 doses on a 0, 1, and 6-month schedule. For hepatitis A, the first shot gives short-term protection within 2–4 weeks; the second shot 6 months later locks in long-term immunity — usually 20+ years. For hepatitis B, the standard schedule is dose 1 at the start, dose 2 one month later, and dose 3 five months after that — the third dose is essential for durable immunity. A newer 2-dose adult hepatitis B vaccine (Heplisav-B) uses shots one month apart and is now available in some countries. A combination hepatitis A + B vaccine also exists and follows a 3-dose schedule (0, 1, 6 months). Missing a dose usually means completing the series later, not restarting.

Most side effects are mild and short-lived — sore arm, tiredness or low-grade fever for a day or two. The most common reactions are soreness, redness or swelling at the injection site, plus mild headache, fatigue, or a slight fever. These usually settle within 24 to 48 hours. Serious side effects are extremely rare. Severe allergic reactions (anaphylaxis) occur in fewer than 1 per million doses. People with a known severe allergy to any vaccine ingredient (like yeast, in the case of the hepatitis B vaccine) should tell their doctor before getting the shot. The vaccine cannot cause hepatitis infection because it contains only viral proteins, not live virus.

Most healthy adults do not need boosters or antibody testing once the full vaccine series is complete. Immunity from both hepatitis A and hepatitis B vaccines usually lasts 20 years or more, and the immune system has memory cells that can respond quickly even if antibody levels drop over time. However, certain high-risk groups — healthcare workers exposed to blood, dialysis patients, people living with HIV or on immunosuppressive drugs, and infants of hepatitis B-positive mothers — should get antibody testing (anti-HBs level) 1–2 months after the final dose, and boosters may be given if the level is below the protective threshold (10 mIU/mL). If you're unsure about your childhood vaccine history, an antibody test can confirm whether you're still protected.

The cyclical fever pattern — classically every 48 hours in P. vivax and P. ovale (tertian fever), or every 72 hours in P. malariae (quartan fever) — is a direct consequence of the blood-stage replication cycle of the parasite. Inside a red blood cell, the malaria parasite (merozoite) matures from ring stage to trophozoite to schizont over a fixed time span specific to the species. When the schizont is fully formed, the red blood cell ruptures, releasing 8–32 new merozoites along with parasite waste products including hemozoin (malaria pigment) and parasite proteins into the bloodstream. It is this sudden mass release — happening simultaneously across millions of infected red cells that started the cycle at the same time — that triggers the immune system to release a surge of inflammatory cytokines (TNF-α, IL-1, IL-6), causing the fever spike, rigors, and sweating. Once the cytokine wave subsides and the newly released merozoites have infected fresh red cells and begun their next cycle, the patient feels temporarily better. P. falciparum is more dangerous partly because its cycle is less synchronised, producing more continuous fever and higher parasite loads. Fever that doesn't fit the classic 48/72-hour pattern doesn't rule out malaria — many P. falciparum infections produce daily or irregular fever.

After an infected Anopheles mosquito bites you, sporozoites injected into the skin enter the bloodstream and reach the liver within 30–60 minutes. Inside hepatocytes (liver cells), each sporozoite undergoes asexual multiplication — a process called exoerythrocytic schizogony — producing thousands of merozoites in a single liver schizont. This liver stage lasts 7–10 days for P. falciparum, and slightly longer (up to 2 weeks) for P. vivax. The merozoites burst out of the liver into the bloodstream and begin infecting red blood cells — this is when blood-stage symptoms begin. The reason P. vivax and P. ovale cause relapses months or even years after the original infection is the hypnozoite — a dormant form of the parasite that remains in the liver cells after the initial infection and does not immediately replicate. Hypnozoites can reactivate weeks to years later (often triggered by immune suppression, stress, or fever from another illness), causing a new blood-stage infection and fresh symptoms despite no new mosquito bite. Primaquine (or tafenoquine) are the only drugs that kill hypnozoites and are essential to prevent P. vivax relapse; however, they can cause haemolysis in G6PD-deficient patients, so G6PD testing is required before prescribing.

No single drug kills the malaria parasite at every stage of its life cycle — effective treatment requires targeting the right stage at the right time. Artemisinin-based combination therapies (ACTs) — the current first-line treatment for uncomplicated malaria — work primarily on the blood stage; they rapidly kill ring-stage and trophozoite-stage parasites across all four Plasmodium species, clearing fever within 24–48 hours. Primaquine has a different role: it targets liver hypnozoites (preventing P. vivax/P. ovale relapse) and kills mature gametocytes in the bloodstream, reducing transmission from treated patients to mosquitoes. This is why WHO recommends adding a single low dose of primaquine to ACT therapy even for P. falciparum, to reduce gametocyte carriage and curb transmission in communities. Chloroquine is now largely ineffective against P. falciparum due to widespread resistance but remains useful for P. vivax in areas without chloroquine-resistant vivax. The emergence of artemisinin partial resistance in Southeast Asia is a serious concern because it affects the ring stage specifically — parasites survive the initial artemisinin exposure and must be cleared by the partner drug (piperaquine, lumefantrine, etc.). Understanding the lifecycle also explains why blood-smear thick films, rapid diagnostic tests (RDTs), and PCR all detect different things — the thick film and RDTs detect blood-stage parasites and antigens, while PCR can detect very low-level parasitaemia at any stage.

Gametocytes are the sexual stage of the malaria parasite — the forms that circulate in human blood and are picked up by female Anopheles mosquitoes during a blood meal. They are clinically silent: gametocytes do not cause fever or any symptoms in the human host. However, they are the only form that can continue the life cycle inside the mosquito — and therefore the only form capable of perpetuating transmission. After an infected blood meal, male and female gametocytes fuse in the mosquito's midgut to form a zygote, which develops into an ookinete, then an oocyst, and finally thousands of sporozoites that migrate to the mosquito's salivary glands ready to infect the next human bite. This mosquito-stage development takes approximately 10–21 days depending on ambient temperature — this is called the extrinsic incubation period. A patient who has been treated with ACT and has cleared blood-stage parasites (and therefore feels well) may still carry gametocytes for 1–3 weeks, remaining infectious to mosquitoes. This is why gametocyte-clearing drugs (primaquine, ivermectin in research settings) are important beyond individual treatment: they are transmission-blocking interventions that protect the community, not just the patient. In India's monsoon season, when Anopheles mosquito density peaks, gametocyte carriage in partially treated or untreated patients is the main driver of malaria outbreaks.

HIV targets CD4 immune cells, uses them as factories, then destroys them — slowly weakening the immune system over years. The virus enters the body through blood, semen, vaginal fluid, or breast milk and locks onto a CD4 T-cell through the CD4 receptor and a co-receptor called CCR5 (or sometimes CXCR4). Once inside, HIV converts its RNA into DNA using an enzyme called reverse transcriptase and inserts that DNA permanently into the cell's own genome. The infected cell then produces thousands of new virus copies before dying, and each new copy goes on to infect other CD4 cells. This is why HIV cannot be cleared by the immune system on its own — once integrated, the viral DNA stays for the cell's lifetime.

CD4 count measures the number of healthy CD4 immune cells per microlitre of blood — the lower it drops, the more vulnerable a person becomes to infections. A healthy adult usually has a CD4 count between 500 and 1,500 cells/µL. HIV progressively kills CD4 cells, and when the count falls below 200, the person is at high risk of opportunistic infections like tuberculosis, pneumocystis pneumonia, cryptococcal meningitis and certain cancers — this is the point at which HIV becomes AIDS. Antiretroviral therapy (ART) stops the virus from replicating, so the CD4 count can recover to normal levels within months to years. CD4 counts are checked every 3–6 months to monitor treatment response and immune recovery.

ART drugs block the virus at different stages of its life cycle, so it cannot multiply — but they cannot remove HIV DNA already hidden inside cells. There are several drug classes, each attacking a different step: entry inhibitors block the virus from binding to CD4 cells; reverse transcriptase inhibitors (both nucleoside and non-nucleoside) stop the virus from converting RNA into DNA; integrase inhibitors stop the DNA from being inserted into the host genome; and protease inhibitors block the assembly of new virus particles. Modern ART combines three or more drugs from different classes to prevent resistance. Consistent daily ART reduces the amount of virus in the blood (viral load) to undetectable levels — at which point the person cannot transmit HIV to sexual partners (U=U, undetectable equals untransmittable).

The virus hides its DNA inside long-lived immune cells in tissues where drugs can't fully reach — these hidden reservoirs are what prevents a true cure. Even when ART suppresses HIV in the blood to undetectable levels, latent virus persists inside a small number of resting CD4 memory cells, in lymph nodes, gut lining and the brain. If ART is stopped, these reservoirs reactivate within weeks and the virus rebounds. Research is exploring several cure strategies: "shock and kill" (waking up latent virus so drugs can eliminate it), gene editing (removing CCR5 or excising HIV DNA), and stem-cell transplants (the approach that cured a handful of patients with HIV plus leukaemia). A widely available cure is still years away, but ART now makes HIV a manageable long-term condition with near-normal life expectancy.

The virus doesn't raise CRP directly — the immune system's flood of inflammatory chemicals does. When SARS-CoV-2 infects lung tissue, immune cells release a burst of pro-inflammatory signals, especially interleukin-6 (IL-6). These signals travel to the liver, which cranks up production of CRP within hours. The stronger the immune response, the higher the CRP climbs. This is why CRP tracks so closely with disease severity — it's an indirect measure of how much systemic inflammation the infection is driving. In severe COVID this response can spiral into a "cytokine storm" that damages the lungs, kidneys and blood vessels, which is why doctors watch CRP carefully alongside oxygen level, D-dimer and clinical symptoms.

Rising CRP tells doctors when to escalate — start steroids, add oxygen, or consider drugs like tocilizumab. In hospitalised COVID patients, CRP is checked daily along with oxygen saturation and chest imaging. Persistently high or rising CRP despite standard treatment suggests severe inflammation and prompts consideration of higher-intensity therapy: intravenous dexamethasone (standard for anyone needing oxygen), remdesivir (for early moderate disease), and IL-6 blockers like tocilizumab or baricitinib (for patients with very high inflammation who are not responding). Falling CRP over 48–72 hours after starting steroids usually means the treatment is working. A CRP that stays high beyond a week, especially with new fever, may point to a secondary bacterial infection, blood clots or another complication that needs its own investigation.

No single blood test tells the whole story in COVID — CRP is best used alongside D-dimer, ferritin, LDH and lymphocyte count. CRP reflects general inflammation; D-dimer reflects clotting activity (raised D-dimer warns of pulmonary embolism, a serious COVID complication); ferritin often mirrors CRP but rises in inflammatory storms; LDH indicates tissue damage; and a dropping lymphocyte count is another warning sign of severe disease. Doctors combine these with oxygen level, respiratory rate, and CT chest findings to get a full picture. Age, kidney disease, obesity and chronic inflammation can all raise baseline CRP, so a single high value must always be interpreted alongside the clinical context — not as a stand-alone verdict.

Get to a hospital or clinic immediately — post-exposure treatment works best within 24 hours and must start within 7 days. If you've had a needlestick injury, unprotected sex with a known hepatitis B-positive partner, or any other significant exposure to blood or body fluids, wash the site with soap and water (do not squeeze or scrub), then go straight to an emergency department or occupational health service. The doctor will assess the exposure, test both you and (if possible) the source person, and decide what post-exposure prophylaxis (PEP) is needed based on your vaccination status. Delay reduces the chance PEP works — every hour matters, especially in the first 24. Don't wait for symptoms; hepatitis B often has no early signs but can still cause serious long-term liver damage.

PEP combines two things — a shot of hepatitis B immunoglobulin (HBIG) for immediate protection, plus the hepatitis B vaccine to build long-term immunity. HBIG contains ready-made antibodies against hepatitis B and starts protecting within hours; it's given as an intramuscular injection, ideally within 24 hours of exposure and no later than 7 days. The hepatitis B vaccine is started at the same time (in a different arm) and follows the standard 3-dose schedule (0, 1 and 6 months). If you've already completed the full vaccine series and have documented immunity, you may need only a booster or nothing at all. If you're only partially vaccinated, you finish the remaining doses along with HBIG. Follow-up antibody testing 1–2 months after the last dose confirms whether you're protected.

Healthcare workers after needlestick injuries, sexual partners of hepatitis B-positive people, and babies born to hepatitis B-positive mothers are the main groups. Nurses, doctors, dentists, lab technicians and cleaners in hospitals face regular occupational exposure risk — needlestick injuries are the most common trigger for PEP. People who share needles for drug use, or who have unprotected sex with a known hepatitis B carrier, also need PEP as soon as possible. Newborns of hepatitis B-positive mothers should get HBIG plus their first vaccine dose within 12 hours of birth — this reduces the mother-to-baby transmission risk from around 90% to under 10%. Anyone in doubt after a possible exposure should treat it as urgent and seek medical assessment; the cost of delayed PEP is chronic hepatitis, which is far harder to manage.

PEP is highly effective when started early — around 85–95% protection against hepatitis B infection if HBIG and vaccine are given within 24 hours. Effectiveness drops the longer treatment is delayed, which is why it's treated as a medical emergency. The exact success rate depends on the type and severity of exposure, the source person's viral load, and the recipient's vaccination status. In healthcare-worker needlestick injuries, PEP prevents the vast majority of infections. For newborns of hepatitis B-positive mothers, timely PEP reduces mother-to-baby transmission risk substantially — from around 20–40% without intervention (rising higher when the mother is HBeAg-positive with high viral load) to under 5%. Follow-up testing at 6 months checks for antibody response and confirms no infection developed. Even in the small number of cases where PEP fails, early detection through follow-up allows prompt treatment and better long-term outcomes.

The core difference is the pathogen: dengue is a virus, malaria is a parasite — and that changes everything downstream. Dengue is caused by any of four serotypes of the dengue virus (DEN-1 to DEN-4), spread by day-biting Aedes mosquitoes. Malaria is caused by Plasmodium parasites (mainly P. falciparum and P. vivax), spread by night-biting Anopheles mosquitoes. Because a virus and a parasite behave differently, the symptoms differ too: malaria produces cyclic fever with chills and sweats, jaundice and anaemia; dengue produces sudden very high fever, pain behind the eyes, rash and a risk of bleeding and shock. Treatment differs completely — malaria has specific parasite-killing drugs; dengue has none, so care is supportive.

Yes — dual infection is uncommon but does happen, especially during monsoon peaks in endemic areas. Both Aedes and Anopheles mosquitoes are active in the same season, and a person can be bitten by both. Co-infection makes diagnosis tricky because symptoms overlap and mask each other; the fever pattern of malaria can be blunted by dengue's rapid onset. Anyone with prolonged fever after mosquito exposure should get tested for both — a malaria smear or RDT plus a dengue NS1/IgM test — instead of assuming only one. Missing one infection while treating the other can be dangerous, especially if platelets are dropping (dengue) while parasites keep multiplying (malaria).

Both can kill, but the danger profile is different — falciparum malaria causes more deaths worldwide; severe dengue kills faster once it turns critical. P. falciparum malaria remains one of the top infectious killers globally, with cerebral malaria and multi-organ failure driving most deaths, especially in children under five. Severe dengue (DHF/DSS) has a lower overall death rate but can go from mild fever to shock within 24 hours during the critical phase around day 3–5, when the fever drops. Both are almost always survivable with prompt hospital care — most deaths from either infection trace back to delayed diagnosis or delayed treatment, not to the pathogen itself being unstoppable.

The five main NANDA-I diagnoses applicable to malaria, in order of priority, are: (1) Hyperthermia — related to systemic response to Plasmodium infection and rupture of erythrocytes releasing pyrogens, as evidenced by temperature above 38.5°C, tachycardia and chills; this is first priority because the cyclical fever spikes (classic 48-hour cycle in P. vivax/ovale, 72-hour in P. malariae) can reach 40–41°C and trigger febrile seizures. (2) Deficient Fluid Volume — related to profuse sweating during fever defervescence, vomiting, and reduced oral intake, as evidenced by dry mucous membranes, decreased urine output and elevated haematocrit; dehydration accelerates haemodynamic compromise. (3) Impaired Tissue Perfusion — related to destruction of red blood cells by the parasite causing haemolytic anaemia, as evidenced by pallor, weakness, and low haemoglobin; in P. falciparum this can progress to cerebral malaria if parasitized cells block cerebral capillaries. (4) Risk for Bleeding — related to thrombocytopaenia (low platelet count) caused by splenic sequestration and immune-mediated platelet destruction; monitor for petechiae, bruising and bleeding gums. (5) Acute Pain — related to myalgia, arthralgia and headache associated with the febrile phase. In GNM/BSc Nursing examinations, always prioritise by Maslow: physiological threats (oxygenation, fluid) before safety, before psychosocial.

The febrile phase of malaria requires concurrent temperature management, fluid replacement, drug administration, and close monitoring — all happening within the same nursing shift. Temperature management: monitor temperature every 1–2 hours during a fever spike; administer paracetamol 650 mg (or as prescribed) for temperature above 38.5°C and document the response; use tepid sponging (30°C water) and a fan; avoid cold water or alcohol sponging (causes shivering and paradoxically raises core temperature). Fluid management: encourage 2–3 litres of oral fluid per day; if the patient is vomiting or obtunded, prepare for IV therapy — Normal Saline or Ringer's Lactate, monitoring intake and output hourly in severe malaria. Antimalarial drug administration: administer as prescribed (Artemisinin-based Combination Therapy — ACT — for P. falciparum; chloroquine or primaquine for P. vivax, with G6PD test required before primaquine to avoid haemolytic reaction); give with food to reduce nausea; do not crush chloroquine tablets. Monitoring: check haemoglobin and platelet count daily in severe malaria; observe for warning signs of cerebral malaria (confusion, seizures, altered GCS) and severe anaemia (Hb below 7 g/dL); check blood glucose in patients on quinine (hypoglycaemia risk); assess urine colour — dark or cola-coloured urine indicates blackwater fever (severe haemolysis) and requires immediate escalation. Document all observations and drug administration times accurately.

Distinguishing severe from uncomplicated malaria is a critical clinical nursing skill because severe malaria requires immediate escalation and IV antimalarials rather than oral ACT. WHO defines severe malaria (almost always P. falciparum) by the presence of one or more of these criteria: (1) Impaired consciousness or unrousable coma — GCS below 10; (2) Prostration — inability to sit up or stand without support in a child who was previously able to; (3) Multiple convulsions — more than 2 within 24 hours; (4) Respiratory distress — deep laboured breathing (acidotic breathing / Kussmaul pattern); (5) Circulatory collapse — systolic BP below 70 mmHg, cold extremities; (6) Abnormal bleeding — spontaneous bleeding from gums, nose or IV sites; (7) Severe anaemia — Hb below 7 g/dL with high parasite density; (8) Haemoglobinuria — dark or black urine without urinary tract infection; (9) Pulmonary oedema confirmed by chest X-ray; (10) Hypoglycaemia — blood glucose below 2.2 mmol/L. Uncomplicated malaria presents with fever, chills, headache, myalgia, vomiting and a positive blood film or RDT — but the patient is conscious, haemodynamically stable, and can tolerate oral medications. Nursing action for severe malaria: immediately notify the physician, prepare IV access, draw blood for FBC, blood glucose, renal and liver function, blood culture, and group and crossmatch; position the patient on their side to protect the airway; have oxygen and emergency resuscitation equipment ready.

Prevention education is essential because malaria relapse (P. vivax has a liver-stage that causes relapse months later) and reinfection are common. Cover five areas: (1) Completing the full drug course — emphasise that stopping antimalarials early because symptoms resolved is the main cause of treatment failure and relapse; for P. vivax, primaquine must be taken for 14 days after the acute phase to eliminate liver-stage parasites (hypnozoites). (2) Mosquito bite prevention — Anopheles mosquitoes bite between dusk and dawn; advise: sleep under a long-lasting insecticidal net (LLIN/ITBN); use DEET-based repellent on exposed skin at night; wear long-sleeved shirts and trousers after sunset; screen windows and doors; eliminate standing water around the home (flowerpots, blocked drains, discarded tyres) where mosquitoes breed. (3) Recognising relapse — P. vivax malaria can recur weeks to months after treatment; teach the patient to seek an RDT or blood smear test if fever with chills returns, and not to self-medicate without confirmation. (4) Travel precautions — if travelling to high-risk areas, take malaria chemoprophylaxis as recommended by a doctor; chemoprophylaxis is different from treatment and must be started before travel. (5) Community role — report suspected cases in the household to the local health worker (ASHA, ANM); indoor residual spraying (IRS) by the health department is a household right in endemic areas.

Everyone aged 50 and above should consider it, and adults 19+ with a weakened immune system are strongly advised to take it. Shingles is caused by reactivation of the varicella-zoster virus that stays dormant after chickenpox infection — around 90% of adults carry it silently. The lifetime risk of developing shingles is roughly 1 in 3, and both risk and severity rise steeply after age 50. Immunocompromised adults (people on chemotherapy, long-term steroids, biologics, HIV, or after organ transplant) can develop shingles much earlier and with worse complications. Anyone who has already had shingles once should still get vaccinated, because recurrence is possible and the vaccine also reduces the risk of postherpetic neuralgia — long-term nerve pain that can last months to years after the rash heals.

Shingrix is a newer, non-live recombinant vaccine that is more effective and safer for immunocompromised people; Zostavax is the older live-virus vaccine. Shingrix is given in two doses 2–6 months apart and offers around 90% protection against shingles and its complications, with efficacy lasting at least 7–10 years. It works in people over 50 and in adults 19+ with a weak immune system. Zostavax is a single-shot live vaccine with lower efficacy (around 51%) that wanes faster; it should not be given to people who are immunocompromised or pregnant. In India both have been available at private hospitals and specialised immunisation centres, though Shingrix availability may vary — check with your doctor about current stock and preferred choice for your health profile.

Yes — Shingrix is recommended for all adults over 50 regardless of chickenpox history, because most adults have already been exposed even if they don't remember. Around 90–99% of adults born before the widespread chickenpox vaccination era carry the varicella-zoster virus silently after childhood exposure. Blood tests for varicella antibodies are not usually needed before Shingrix — the guidance is simply to vaccinate everyone 50+. If someone is confirmed to have never had chickenpox and never been vaccinated against it, they should get the chickenpox vaccine (varicella) first rather than the shingles vaccine, because there's no dormant virus to reactivate — and the two vaccines protect against different clinical situations.

Most side effects are mild and last 1–3 days — sore arm, tiredness, muscle aches, mild fever or headache. Shingrix is known for causing a stronger local reaction than most adult vaccines because of the adjuvant that boosts immune response — around 1 in 6 people feel unwell enough after the shot to skip normal activities for a day or two. This is not dangerous; it's actually a sign the vaccine is working. Symptoms usually settle within 48 hours with rest, fluids and paracetamol. Serious reactions like anaphylaxis are extremely rare. People with a known allergy to any vaccine component should tell their doctor first. The temporary discomfort is far outweighed by the roughly 90% protection against shingles and the misery of postherpetic neuralgia.

Microscopy of a stained blood smear is still considered the gold standard for confirming malaria and identifying the exact Plasmodium species. A trained lab technician examines both thick and thin smears — thick smears pick up even low parasite loads, while thin smears show the species (falciparum, vivax, ovale, malariae, knowlesi). PCR is technically more sensitive and can catch very low-level infections and mixed infections, but it's expensive, slow and needs a specialised lab, so it's used mainly in research or difficult cases. Rapid diagnostic tests (RDTs) are less sensitive than microscopy but perform very well for typical clinical cases and are much faster. For most patients, an RDT plus a confirmatory smear gives the best real-world accuracy.

An RDT looks for parasite proteins in a drop of blood and gives a coloured line within 15–20 minutes. A finger-prick sample is placed on a test strip that contains antibodies designed to grab specific malaria antigens — usually HRP2 (which detects P. falciparum) and pLDH (which detects all Plasmodium species). If the antigen is present, the antibodies bind it and a visible line appears in the result window, similar to how a home pregnancy test works. RDTs need no microscope, no electricity and minimal training, which is why they're the workhorse of malaria screening in clinics, camps and remote areas. False negatives can happen with very low parasite loads or with rare falciparum strains that don't produce HRP2, which is why a negative RDT in a symptomatic patient still needs a blood smear.

It depends on the test — RDTs in 15–20 minutes, blood smears in 1–2 hours, PCR in a day or more. RDTs are the fastest, giving a yes/no answer within minutes at the bedside. Blood smear microscopy usually takes one to two hours from sample collection to result, longer if the lab is busy or if the first smear is negative and needs a repeat 12 hours later. PCR gives the most detailed information (species, parasite load, drug-resistance markers) but takes several hours to a day because DNA has to be extracted and amplified in a lab. LAMP is a newer molecular test that runs in about an hour and is being rolled out in more centres. For any suspected malaria, treatment should not wait for slow tests — doctors often start therapy on RDT positive results and confirm later.

A raised CRP usually means more inflammation in the body — in COVID-19, it often signals more severe lung involvement. CRP (C-reactive protein) is a protein your liver releases whenever there's active inflammation from infection, injury or immune activity. In a healthy adult it stays below 5–10 mg/L. In mild COVID, CRP typically stays under 40 mg/L. Values above 40–100 mg/L suggest moderate disease with likely pneumonia, and levels above 100 mg/L are strongly linked to severe COVID pneumonia, higher oxygen needs and ICU admission. A single CRP reading has limits, but rising CRP over 24–48 hours is one of the strongest early warning signs of worsening COVID and often triggers the decision to admit, escalate oxygen or start anti-inflammatory drugs like dexamethasone.

The Widal test has significant limitations and is now considered unreliable when used alone for typhoid diagnosis. False positives are common — endemic areas have background elevated titers from past exposure or vaccination, and cross-reaction occurs with other Salmonella species, malaria, dengue, and viral infections. False negatives happen in the first week of illness (before antibody rise), in immunocompromised patients, and with early antibiotic treatment. Baseline elevated titers are a real problem: in endemic Indian regions, 5-25% of asymptomatic healthy people have Widal titers of 1:80 or higher just from past exposure — so a single elevated titer is meaningless. Proper interpretation requires paired samples 7-14 days apart showing a 4-fold rise — rarely done in practice. The low cost of Widal makes it commonly used but leads to overdiagnosis and unnecessary antibiotics. Modern gold standard: BLOOD CULTURE — collect 3-5 ml blood in specialised bottles before antibiotics; positive in 70-90% of cases in the first week, declining thereafter; identifies exact organism and antibiotic sensitivity. Better alternatives: blood culture always preferred; bone marrow culture (over 90% sensitivity even after antibiotics); Typhidot IgM (more specific than Widal, positive from day 3-5); Enterocheck WB rapid test; IDL Tubex immunoassay. WHO recommends against Widal test where blood culture is available.

Diagnostic approach: (1) Blood culture in first week (best sensitivity 70-90%) — do BEFORE any antibiotics; (2) If already on antibiotics or blood culture negative but strong suspicion — bone marrow culture (>90% sensitivity even after antibiotics); (3) Typhidot IgM as adjunct (positive day 3-5); (4) Widal only if better tests unavailable — interpret with caution using paired samples showing 4-fold rise. Clinical clues: gradual stepwise fever rise over week, relative bradycardia (pulse slower than expected for fever), abdominal pain, constipation initially then diarrhoea (‘pea-soup’ stools classic), rose spots (small blanching macules on trunk — often missed), splenomegaly, hepatomegaly. Treatment (based on culture sensitivity): (1) UNCOMPLICATED CASES — Azithromycin 500mg once daily for 7-10 days (first-line India due to widespread fluoroquinolone resistance); OR Cefixime 200mg BD for 10-14 days; (2) COMPLICATED/SEVERE — Ceftriaxone 2g IV once daily 10-14 days; ICU admission if severe; (3) MDR/XDR TYPHOID (increasing in India, especially Sindh-linked strains) — meropenem or azithromycin per sensitivity; specialist care needed; (4) DEFERVESCENCE takes 3-7 days on appropriate antibiotic; incomplete response = check compliance, sensitivity, complications; (5) SUPPORTIVE CARE — hydration, nutrition, paracetamol for fever, monitor for complications (intestinal perforation, bleeding, myocarditis, hepatitis). Complications: 10-15% untreated cases develop severe complications; intestinal perforation 1-3% (surgical emergency).

Typhoid remains endemic across India with 400,000+ cases annually. Prevention: (1) VACCINATION — Multiple vaccines available: (a) Typbar TCV (Bharat Biotech) — typhoid conjugate vaccine; single dose from 6 months; long-lasting protection; ~85% effective; WHO-prequalified; (b) Typhim Vi / Typherix — polysaccharide vaccine; single dose age 2+; needs booster every 3 years; ~55-72% effective; (c) Vivotif (oral live typhoid) — 4 capsules alternate days; less used in India. RECOMMENDED FOR: children 9 months+ under UIP (recently added), travellers to endemic areas, food handlers, laboratory workers, healthcare workers, household contacts of chronic carriers, high-risk residents. (2) FOOD & WATER HYGIENE — (a) Drink only boiled/filtered water (RO + UV) or sealed bottled water from trusted brand (check seal, expiry); (b) Avoid ice from unknown source; (c) Avoid street food, especially cut fruits, chutneys, sauces sitting out; (d) Eat only thoroughly cooked hot food; (e) Wash hands with soap before eating, after toilet; (f) Peel your own fruits; (g) Avoid raw vegetables/salads at questionable restaurants. (3) SANITATION — safe waste disposal, treated water supply, hand hygiene education. (4) CARRIER DETECTION — some patients become chronic carriers (Salmonella typhi in gallbladder); stool culture screening for food handlers, healthcare workers. (5) OUTBREAK RESPONSE — public health notification, contact tracing, source investigation, mass vaccination if indicated. India needs multipronged approach: universal typhoid conjugate vaccination in childhood + hygiene infrastructure + antimicrobial stewardship to prevent XDR typhoid emergence.

Test selection depends on timing of illness: (1) DAY 1-5 of fever (early illness) — NS1 ANTIGEN test is BEST; detects dengue viral protein in blood before antibodies form; sensitivity 70-90% days 1-3, drops after day 5; sample = single blood draw; (2) DAY 5+ of fever — IgM antibody test becomes positive; detects immune response; specific for recent infection; (3) IgG antibody — high in secondary dengue (previous dengue + new infection) — indicates increased severity risk; useful in outbreak epidemiology; (4) RT-PCR (viral RNA) — most accurate early (day 1-5) but expensive; typically reserved for confirmed severe cases, atypical presentations, research; not routine; (5) NS1 + IgM combination panel — covers both early and later phases; commonly ordered when timing unclear. ADDITIONAL essential tests during dengue: (1) CBC with platelet count — repeat every 12-24 hours; watch for drop below 100,000 (warning), below 20,000 (bleeding risk); (2) Hematocrit — rising Hct indicates plasma leakage (severe dengue warning); (3) LFT — elevated in most dengue; hepatitis component; (4) Coagulation profile if bleeding suspected. Modern dengue management is guided by daily monitoring, not just diagnostic test at admission.

Dengue phases and warning signs: FEBRILE PHASE (Days 1-3): sudden high fever 39-40°C, severe body ache, headache, retro-orbital pain, joint pain (‘breakbone fever’), nausea, vomiting, rash. Most patients recover from here. CRITICAL PHASE (Days 3-6): as fever DECREASES (defervescence), 5-10% develop severe complications — PLASMA LEAKAGE. Warning signs of severe dengue: (1) Persistent vomiting (>3 episodes in hour); (2) Severe abdominal pain (constant, not just cramping); (3) Bleeding — nose, gums, bruising, blood in vomit/stool/urine, menstrual excess; (4) Restlessness or lethargy; (5) Cold clammy extremities; (6) Rapid weak pulse, drop in BP; (7) Difficulty breathing; (8) Marked drop in platelet count (<50,000); (9) Rising hematocrit >20%; (10) Reduced urine output. RECOVERY PHASE (Days 6-10): fluid reabsorbs, rash may recur, gradual improvement. When to seek emergency care immediately: any of the warning signs above; especially if fever suddenly drops but patient appears WORSE (not better) — critical phase warning; sudden severe abdominal pain; bleeding from any site; altered mental state; dizziness on standing. India-specific: dengue outbreaks worst in monsoon (July-October); Bangalore, Delhi, Kolkata, Chennai, Ahmedabad among high-burden cities; mosquito breeding in stored water containers (bucket, cooler, flower pot, tyre); Aedes mosquito bites during daytime especially early morning + late afternoon; use repellent (DEET 20-30% or picaridin), full-sleeve clothing, mosquito nets.

Dengue treatment is supportive — NO specific antiviral: (1) FLUIDS are the cornerstone — oral in mild cases (WHO ORS, coconut water, dal ka pani, buttermilk, fresh fruit juice), IV in severe cases (crystalloids like Ringer’s lactate); careful fluid balance critical — under-hydration + shock danger, over-hydration + pulmonary oedema danger; (2) PARACETAMOL for fever (500-1000mg every 4-6 hours, max 4g/day); AVOID aspirin, ibuprofen, other NSAIDs (increase bleeding risk); AVOID intramuscular injections (haematoma risk); (3) MONITORING — daily CBC (platelet + hematocrit), symptom assessment, fluid intake/output balance, vital signs; frequency depends on severity; (4) HOSPITALISATION indicated for: any warning sign, high-risk patients (pregnancy, elderly, comorbidities), inability to maintain oral hydration, platelet count <50,000. PLATELET TRANSFUSION — commonly over-used; guidelines: (1) Platelet transfusion NOT indicated for count alone (up to 20,000-30,000 without bleeding — no transfusion needed); (2) Indicated for: active bleeding + thrombocytopenia; platelet count <10,000 with high-risk factors; before invasive procedures; (3) Random donor platelets are less expensive but need multiple units to raise count meaningfully; single donor platelets (SDP) are more expensive; (4) Papaya leaf extract — no strong evidence but widely used; likely safe; do NOT replace medical care. FLUID MANAGEMENT: crystalloids first-line; colloids if inadequate response; blood transfusion if bleeding-related anaemia. RECOVERY: most uncomplicated cases recover 7-10 days; fatigue can persist weeks. Post-dengue: rare complications include prolonged fatigue, joint pain, hair loss; secondary dengue increases severity risk — dengue vaccination (Dengvaxia, QDenga) only for previously infected individuals in specific contexts.

NS1 (non-structural protein 1) is a protein produced by the dengue virus itself — not by the patient's immune system. Because the virus starts replicating immediately after infection, NS1 floods the bloodstream within hours and is detectable in blood from day 1 of fever, sometimes even a few hours before symptoms start. This is the key advantage over antibody tests: antibody-based tests (IgM/IgG) detect the body's response to dengue, which takes 4–7 days to build up to detectable levels. In the first 5 days of illness — when fever is high, the patient is most unwell, and the clinical picture is unclear — the NS1 test is the primary diagnostic tool. After day 5, NS1 levels fall as the immune system clears the protein, and antibody tests (IgM ELISA or rapid combo cards) take over as the more reliable option. All four dengue serotypes (DENV-1 to DENV-4) produce NS1, so the test works regardless of which serotype is circulating in the current outbreak.

A positive NS1 test means the dengue virus is actively replicating in the blood right now — this is a confirmed dengue infection, not a past exposure or a false alarm from vaccination. The next steps depend on clinical severity. For most patients with uncomplicated dengue (fever + body aches + rash, no warning signs), a positive NS1 leads to: admission or close home monitoring with daily or twice-daily platelet and haematocrit checks, oral hydration with 2–3 litres of fluid per day (ORS, coconut water, water), paracetamol for fever (never aspirin or ibuprofen — these increase bleeding risk by inhibiting platelets), and strict bed rest. Warning signs that require immediate hospitalisation regardless of test result: severe abdominal pain, persistent vomiting, bleeding from gums or nose, blood in urine or stools, sudden drop in platelet count below 20,000, or altered consciousness. A single positive NS1 is sufficient to start treatment — no second test is needed to confirm. However, because NS1 cross-reacts with other flaviviruses (Zika, West Nile, Japanese encephalitis), a positive result in a non-dengue-endemic area or during a known Zika outbreak should be interpreted carefully alongside clinical context.

Yes — a negative NS1 does not rule out dengue, and this is the most important limitation to understand. False negatives happen in two situations: (1) Testing too late — NS1 is most detectable in days 1–5 of fever; by day 6–7 the immune system starts clearing it and levels fall below the test's detection threshold even though the patient is still sick. If you test on day 6 or later and the NS1 is negative, a dengue IgM antibody test should be added. (2) Secondary dengue infection — people who have had dengue before (a different serotype) tend to produce a faster and stronger antibody response in the second infection, which binds and clears NS1 quickly, lowering detectable levels and causing NS1-negative results even in early illness. In a secondary infection, dengue IgG is typically elevated from the start. Rapid combination cards (NS1 + IgM + IgG on one strip) are more accurate than NS1 alone in secondary infections because they pick up the early IgG signal that primary infection cards miss. If clinical suspicion is high — high-grade fever in a dengue-endemic area during outbreak season, with severe myalgia, retro-orbital pain and rash — treat as probable dengue and repeat testing the next day even if the first result is negative.

There are three main dengue test types, each useful at a different point in the illness. NS1 antigen test: best in days 1–5; detects active viral replication; a positive is diagnostic; available as rapid card test (result in 15–20 minutes) or ELISA (more quantitative, used in labs). IgM antibody test: detects the body's primary immune response; turns positive from about day 4–5 and peaks at 2–3 weeks; best for confirming dengue in the second week of illness or if the patient presents late; a positive IgM alongside symptoms in an endemic area is clinically diagnostic. IgG antibody test: detects past or secondary infection; already high at illness onset in secondary dengue; useful for epidemiological studies and to identify secondary infections. In practice, most hospitals and clinics now use combination rapid cards (NS1 + IgM + IgG) from a single finger-prick sample — these cover both early and late presentations in one test. Blood culture is not used for dengue (the virus cannot be easily cultured in routine labs). PCR (RT-PCR) is the most accurate test but expensive, slow (24–48 hours), and reserved for severe or unusual cases, research, or outbreak investigation where serotype identification matters.

The top three NANDA-approved diagnoses for a febrile patient are Hyperthermia, Risk for Deficient Fluid Volume, and Impaired Comfort. Hyperthermia (body temperature above 38.3°C / 101°F) is typically the primary diagnosis because it is the defining clinical problem and drives most interventions — antipyretic administration, tepid sponging, light clothing and bedding, and environmental cooling. Risk for Deficient Fluid Volume is second-priority because fever accelerates insensible fluid loss through sweating and increased respiratory rate; without aggressive oral or IV rehydration the patient can dehydrate rapidly. Impaired Comfort addresses the associated headache, myalgia, chills and restlessness. Secondary diagnoses to consider include Risk for Febrile Seizure (in children under 5 or with a prior seizure history) and Deficient Knowledge if the patient and family cannot yet identify warning signs. In GNM and BSc Nursing examinations, always state the diagnosis in NANDA format: problem + related factor + as evidenced by (PES format).

Nursing interventions for the Hyperthermia diagnosis combine pharmacological and non-pharmacological strategies. Start by monitoring core temperature every 2–4 hours (or every 1 hour during a febrile spike) using the same route each time for consistency. Administer antipyretics — paracetamol 650 mg or ibuprofen — as prescribed, documenting time, dose, route and effect. Non-pharmacologically: apply tepid water sponging (30°C water — not cold, which causes shivering and raises core temperature), provide lightweight cotton clothing, open windows or use a fan, and keep the room temperature at 22–24°C. Encourage oral fluids 2–3 L per day unless contraindicated; if the patient cannot tolerate oral fluids, assist with IV line preparation as ordered. Remove excess bedding. Monitor for shaking chills, which precede a temperature spike — apply a light blanket during rigors to prevent energy expenditure from violent shivering. Document all temperatures and interventions in the nursing notes and report a temperature above 39.5°C or failure to respond to antipyretics within 1 hour to the physician.

Evaluation criteria are directly tied to the expected outcomes set during planning. For Hyperthermia the expected outcome is: body temperature returns to and remains within 36–37.5°C within 2–4 hours of intervention. You evaluate this by charting serial temperatures — if the downward trend is consistent and the patient reports less discomfort, the intervention is working; if temperature remains above 38.3°C after two antipyretic doses plus physical cooling, escalate to the physician. For Fluid Volume the expected outcome is: urine output ≥ 30 mL/hour, moist mucous membranes, stable pulse and blood pressure. Check skin turgor and urine colour as quick bedside indicators. For Impaired Comfort the expected outcome is: patient reports pain/discomfort ≤ 3 on a 0–10 scale. If any outcome is not met within the timeframe, the care plan must be revised — reassess the underlying cause of fever (is there a new focus of infection?), review medication efficacy, and consider ordering additional diagnostic tests such as blood culture or CBC. For nursing examination answers, explicitly state the evaluation statement: 'Goal met / partially met / not met' with supporting evidence.

Patient and family education is a core component of the NCP and is frequently examined in GNM and BSc Nursing papers. Key teaching points: (1) How to measure temperature correctly — axillary, oral or tympanic; when to use each site; and what number warrants calling a doctor (>38.5°C in adults, >38°C in infants under 3 months). (2) Antipyretic use: correct dose of paracetamol for the patient's weight, do not exceed 4 g/day in adults, do not give aspirin to children under 12 due to Reye's syndrome risk. (3) Hydration: drink at least 2–3 litres of water, coconut water, oral rehydration solution or clear soup daily; avoid alcohol and caffeinated drinks which increase fluid loss. (4) Warning signs requiring immediate return to hospital: fever above 40°C, febrile convulsion, stiff neck, severe headache, persistent vomiting, or rash — these may indicate meningitis, encephalitis, or severe dengue, not simple pyrexia. (5) Complete the antibiotic course if one was prescribed — stopping early causes resistance and relapse. Document that education was given and the patient/family demonstrated understanding (teach-back method).

H3N2 is a subtype of influenza A virus circulating globally. It emerged in 1968 as a pandemic strain (Hong Kong flu) and has continued as a seasonal flu virus with periodic strain updates. Compared to other flu types: H3N2 tends to cause more severe illness than H1N1 (swine flu) in elderly and vulnerable populations, with higher hospitalisation and mortality rates; H1N1 more affects younger adults and children; influenza B typically causes milder illness; H3N2 evolves faster (antigenic drift), so vaccines need annual updates and effectiveness varies year-to-year (typically 30-60%). India-specific patterns: the Feb-April 2023 H3N2 outbreak caused significant illness across Karnataka, Maharashtra, Tamil Nadu, and Delhi; cases usually surge in monsoon (July-Sept) and post-monsoon (Oct-Nov); the 2023 outbreak had unusually severe respiratory symptoms with prolonged cough (3-4 weeks); co-circulation with COVID, adenovirus, and RSV made clinical differentiation difficult without testing. Typical symptoms: sudden fever (often 102-104°F), dry cough (can be severe or persistent), sore throat, body ache, extreme fatigue, headache, chills. Acute symptoms last 3-7 days; cough may persist 2-4 weeks.

Diagnosis: most cases are managed clinically without testing — symptoms plus community outbreak context are sufficient. When testing is needed: RT-PCR for influenza A/B is most accurate and identifies specific subtype, typically 4-12 hour result. Rapid Influenza Diagnostic Tests (RIDT) give results in 15-30 minutes with lower sensitivity (60-70%) than RT-PCR but useful in clinical decision-making. Multiplex respiratory panels (flu A/B + COVID + RSV + adenovirus) are useful when differentiating is important. Treatment: OSELTAMIVIR (Tamiflu) 75 mg twice daily for 5 days in adults (weight-based child dose) is MOST EFFECTIVE when started within 48 hours of symptom onset; reduces illness duration by 1-2 days, hospitalisation risk by 40-50%, and secondary complications — especially valuable for high-risk patients (elderly, pregnant, chronic disease, immunocompromised). ZANAMIVIR (inhaled) is an alternative — not preferred in asthma/COPD. Baloxavir is newer, single-dose, limited availability. Symptomatic: paracetamol for fever (avoid aspirin in children — Reye syndrome risk); adequate fluids, rest; avoid dry cough suppressants unless disrupting sleep. Antibiotics have NO role for viral flu unless bacterial complication (pneumonia, sinusitis, otitis) develops — over-prescription is a significant issue. Hospitalization needed if: severe respiratory distress, hypoxia (SpO2 under 94%), altered mental state, dehydration, or high-risk patient with severe symptoms.

Flu vaccine indications in India (per IAP, IAPSM, ICMR recommendations): PRIORITY GROUPS (strongly recommended): (1) Adults 65+ years; (2) Pregnant women (any trimester, protects both mother and baby); (3) Chronic disease patients — diabetes, heart disease, kidney disease, liver disease, cancer, HIV, immunosuppression, chronic lung disease (asthma, COPD); (4) Healthcare workers; (5) Immunocompromised patients and their household contacts; (6) Long-term care facility residents; (7) Children 6 months to 5 years (paediatric formulations available). GENERAL RECOMMENDATION: All adults benefit from annual flu vaccine, especially if living with vulnerable persons. Vaccine options in India: (1) TRIVALENT — protects against 3 strains (2 A + 1 B); older; (2) QUADRIVALENT — protects against 4 strains (2 A + 2 B); more comprehensive; standard now; (3) Adjuvanted (Fluad, Fluzone High-Dose) — for 65+; enhanced immune response; (4) Brands: Vaxigrip Tetra (Sanofi), FluQuadri (Sanofi), Influvac (Abbott), NasoVac (Serum Institute, live attenuated intranasal for children 2-17). Timing: annual vaccination in September-October preferred (before flu season); protects for the season. Contraindications: severe allergic reaction to previous flu vaccine; severe egg allergy (though egg-free vaccines now available); acute severe illness (postpone). Common misconceptions: (1) ‘Flu vaccine gives you flu’ — FALSE; inactivated vaccine cannot cause flu; some mild flu-like reactions common but transient; (2) ‘Vaccine 100% prevents flu’ — FALSE; 30-60% typical effectiveness varying by year; but reduces severity, hospitalisation, and death substantially; (3) ‘Getting flu naturally is better than vaccine’ — FALSE; flu can cause serious complications even in healthy adults. Vaccine covered under most corporate health insurance and IRDAI-approved policies.

Not necessarily — a positive Widal test means antibodies against Salmonella were found in your blood, but this does not always mean active typhoid infection. The Widal test has a significant false-positive problem, particularly in India and other endemic regions, for three reasons: (1) Previous typhoid infection or vaccination — H antibodies (flagellar) persist for years after a past infection or a typhoid vaccine, so someone with old immunity will test positive even without a current infection; (2) Cross-reactivity — other infections including malaria, dengue, liver disease, rheumatoid arthritis, and some viral fevers can trigger antibodies that react with Salmonella antigens in the Widal test; (3) Endemic area effect — people living in typhoid-endemic areas like urban India have baseline antibody titres from repeated low-level exposure, meaning even a titre of 1:80 or 1:160 may be normal for that population. What matters is the pattern: O antibodies (somatic) rising in the first week of illness suggest active infection more strongly than H antibodies alone. A single positive titre is not sufficient for diagnosis — a fourfold rise in titre between two samples taken 5–7 days apart is the most reliable Widal-based evidence of active disease. Always confirm with blood culture before starting antibiotics if the clinical picture is unclear.